JUN 2 7 2005

FAX TRANSMITTAL

Date:

June 27, 2005

To:

Rebecca Cook

U.S. Patent & Trademark Office

Fax: Voice: 571-273-8300 571-272-0571

From:

Raymond N. Nimrod

Fax:

rnimrod@jenner.com

Voice:

312 923-8406 312 923-8306

Our Ref. No.

31140B

Employee Number:

148188

Client Number:

8888-148188

Important: This message is intended only for the use of the individual or entity to which it is addressed, and may contain information that is attorney work product, privileged, confidential, and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, or the employee or agent responsible for delivering the message to the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone, and return the original message to us at the above address via postal service. Thank you,

Message:

Serial No.:

10/051662

In Reference to Applicant: Rodriguez, et al.

Filed:

January 18, 2002

For: Prevention of Ovarian Cancer by Administration of a Vitamin D Compound

Group Art Unit: 1614

Total number of pages including this cover sheet:

Time Sent:

If you do not receive all pages, please call: 312 222-9350

Sent By: Pat Sotiropoulos

Secretary: Pat T. Sotiropoulos

Extension: 6873

RECEIVED CENTRAL FAX CENTER

3125270484

P.03

JUN 2 7 2005

PTO/SB/21 (09-04) Approved for use through 07/31/2008. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Index the Papenwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Application Number 10/051,662 TRANSMITTAL Filing Date January 18, 2002 First Named Inventor **FORM** Rodriguez et al Art Unit 1614 Examiner Name Rebecca Cook (to be used for all correspondence after initial filing) Attorney Docket Number 31140-B Total Number of Pages in Thia Submission **ENCLOSURES** (Check all that apply) After Allowance Communication to TC X Fee Transmittel Form Drawing(s) Appeal Communication to Board Licensing-related Papers Fee Attached of Appeals and Interferences Appeal Communication to TC X (Appeal Notice, Brief, Reply Brief) Petition Amendment/Reply Petition to Convert to a Proprietary Information After Final Provisional Application Power of Attorney, Revocation Status Letter Affidavils/declaration(s) Change of Correspondence Address Other Enclosure(s) (please Identify X Terminal Disclaimer Extension of Time Request below): Request for Refund USPTO Credit Card Payment Express Abandonment Request FORM CD, Number of CO(s) Information Disclosure Statement Landscape Table on CD Certified Copy of Priority Remarks Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name Jenner & Block Signature Printed name Raymond N. Nimrod Date Reg. No. 987 CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: Signature Date Typed or printed name <u>6/27/05</u> Raymond N. Nimrod

This collection of information is required by 37 CFR 1.6. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidendality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or auggestions for reducing this burden, should be sent to the Chief Information Officer. U.S. Patent and Tradement Office, U.S. Department of Committee, P.O. Box 1450, Alexandria, VA 22319-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Committee over 1450 and 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

RECEIVED CENTRAL FAX CENTER₃₁₂₅₂₇₀₄₈₄

P.02

JUN 2 7 2005

PTC/SB/17 (12-04v2)
Approved for use through 07/31/2006, OMB 0851-0032
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
O a callerding of information unless a displays a valid OMB control of the control

Under the Paneswork F		NO DESCRIP ALB LEGITIES IN I	Missinna to Al Calleration		te if Known			
Foos pursuant to the Co	Effective on 12/08/20 onsolidated Appropriat	104. Bons Act, 2005 (H.R. 4618).					i	
FFF 1	TRANS	MITTAL	Application Numi Filing Date	1/18/20				
•	For FY 20		First Named Inve		o C. Rodrigi	187		
	FOIFI Z)US	Examiner Name		ca Cook			
Applicant claims	small entity status.	See 37 CFR 1.27			ca <u>Cook</u>	<u> </u>		
TOYAL AMOUNT OF	PAYMENT (\$)	1 325 00	Art Unit	1614	<u> </u>		•	
TOTAL AMOUNT OF PAYMENT (\$) 1,325.00 Attamey Docket No. 31140B								
METHOD OF PAYMENT (check all that apply)								
Check ✓ Credit Card Moncy Order None Other (please identify):								
Deposit Account Deposit Account Number: Deposit Account Name:								
For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)								
Charge fee(s) Indicated below Charge fee(s) Indicated below, except for the filling fee								
Charge any additional fee(s) or underpayments of fee(s) Credit any overpayments								
WARNING: Information on this form may become public. Credit card information ahould not be included on this form. Provide credit card information and authorization on PTO-2038.								
FEE CALCULATE								
		EXAMINATION FEES		· · · · · · · · · · · · · · · · · · ·				
	FILING I	fees sea	RCH FEES	EXAMINATI	ON FEES	BBONNER 0000006 10	OF LEAD	
Application Type	<u> </u>	imail Entity Fee (\$) Fee	Small Entity (5) Fgg (5)	Fee (\$)	Egg.(\$)	Fees Paid (\$)	021665	
Utility	300	150 500		200	## FC: 2201 ##06C: 2202		166.68	
Design	200	100 100	50	130	65		1225.00 0	
Plant	200	100 300	150	160	80			
Reissuc	300	150 500	250	600	300			
Provisional	200	100	0	0	0		1	
2. EXCESS CLAIM FEES Small Entity								
Fee Description Each claim over 20 (including Reissues) Fee (\$) 50 25								
Each claim ove	r 20 (including K ent claim over 3 (including Reissues)			200	100		
Each independent claim over 3 (including Reissues) Multiple dependent claims						180	1	
Total Claims 30	Extra Clair		ee Pald (\$)			pendent Claims		
79 - 30 o	r HP = 49	x <u>25</u> = <u>\$</u>	1.225.00.		<u>Fee (\$)</u>	Fee Pald (\$)		
HP = highest number of total cialms paid for, if greater than 20. Indep. Claims 4. Extra Claims Fee (\$) Fee Paid (\$)								
5 - 3 or HP = 1 x \$100.0 = \$100.00 HP = highest number of Independent claims paid for, if greater than 3.								
3 APPLICATION SIZE FEE								
If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50								
sheets or fraction thereof. Sec 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).								
Total Sheets Extra Sheets Number of each additional 50 or fraction thereof Fee (5) Fee Paid (5)								
- 100 = /50 = (round up to a whole number) x = 4. OTHER FEE(S) Fees Paid (\$)								
Non-English Specification, \$130 fee (no small entity discount)							1	
Other (e.g., late filing surcharge):								
SUBMITTED BY								
Signature	Ta /	Tol	Registration No. (Attorney/Agent)	1,987	Telephon	9 312-927-5833	_	
Name (Print/Type) Ra	ymorid N. Nimrod		, , ,		Date Jun	e 27, 2005	J	

This collection of information is required by 37 CFR 1.136. The information is required to obtain or retein a banefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 30 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer. U.S. Patent and Trademark Office, U.S. Department of Commence, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

JUN-27-2005 14:06

JENNER & BLOCK LLP

RECEIVED
CENTRAL FAX CENTER

3125270484

P.05

Serial No.: 10/051,662

JUN 2 7 2005

Our File No. 31140-B

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Rodriguez, et al.)
Serial No.:	10/051662) Examiner: R. Cook
Filed: Januar	ry 18, 2002) Group Art Unit: 1614
	ntion of Ovarian Cancer by nistration of a Vitamin D Compound	

Commissioner For Patents P.O. Box 1450 Alexandria, VA 22313-1450

AMENDMENT AND RESPONSE

Applicants thank the Examiner for conducting the interview with Applicant Gus

Rodriguez and his undersigned representative. Applicants are submitting an Information

Disclosure Statement concurrently herewith by Express Mail.

Dr. Rodriguez has worked diligently since the interview to draft claims based on the distinguishing concepts discussed at the interview. The new claims include five independent claims. Each independent claim incorporates at least one limitation that distinguishes over the Need reference. Dr. Rodriguez has drafted the claims with possible products in mind that he desires to bring to the clinical level. Allowance of the claims, which we believe to be distinguished over the prior art, would make it more possible to advance such products.

Dr. Rodriguez respectfully requests that, if possible, the Examiner consider allowance of the newly submitted claims in this application. Dr. Rodriguez also would certainly welcome the possibility of another interview with the Examiner to discuss these new claims.